© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#CROI 2007
Click Here for More Conferences
Click Here for CROI Online
HIV: The Basics
The U.N. General Assembly Hall during the High-level Meeting on HIV/AIDS.

Conferences

Transcript: The Skinny on Metabolic Complications

part I about TH-9507, an experimental drug for reducing fat around the gut part II about Fosamax hel

Transcript: The Plot Thickens: HIV Treatment Challenges

Dr. Calvin Cohen discusses Kaletra vs. Sustiva, the newly infected showing HIV drug resistance, and HIVers dying from non-AIDS cancers

Diary of a Doc: On the Origins of HIV

Thoughts on the sophisticated genetic research that is providing experts with tools they need to unwrap the mystery of the origins of HIV.Â...

The Plot Thickens: HIV Treatment Challenges

Dr. Calvin Cohen discusses Kaletra vs. Sustiva, the newly infected showing HIV drug resistance, and HIVers dying from non-AIDS cancers

Study Finds Viread Advantages in Black Patients

An analysis of two Gilead-sponsored studies suggests that black HIV-positive patients have a better chances of an undetectable viral load afte...

The Skinny on Metabolic Complications

Dr. Don Kotler discusses news from CROI about lipodystrophy, bone loss, and metabolic problems

Transcript: What’s New? Update on Experimental Agents

Dr. Cal Cohen discusses the new integrase & CCR5 inhibitors, and a new non-nuke

What’s New? Update on Experimental Agents

Dr. Cal Cohen discusses the new integrase & CCR5 inhibitors, and a new non-nuke

Twice-Daily Kaletra Possibly Better for Some Patients

An ACTG study indicates that once-daily and twice-daily Kaletra are comparable in patients over 48 weeks of treatment, but also suggests that...

Baraclude Induces HIV Drug Resistance

New research concludes that hepatitis B virus (HBV) treatment Baraclude (entecavir) is active against HIV, suggesting that that the drug will...

Study Says Less Fat for Lower Lipids

While HIV meds play a role in the high rates of cholesterol and triglyceride problems being seen in HIV-positive people, it also appears that...

HIV+ Less Responsive to Lipid-Lowering Meds

Northern California researchers have reported that HIV-positive patients are less likely to benefit from lipid-lowering therapy than their HIV...

Diary of a Doc: New Strategies for HIV-Herpes Coinfection

MD turns his gaze to the recent spate of data promoting the use of anti-herpes drugs to reduce HIV transmission and disease progression.

Non-Nuke TMC-278 Comparable to Sustiva

Tibotec’s experimental NNRTI performs well in a clinical trial pitting it against standard-of-care Sustiva in treatment-naive patients. 

Integrase Inhibitor Elvitegravir (GS-9137) Shows Well

Researchers shared promising 24-week clinical trial data involving Gilead’s integrase inhibitor, elvitegravir (GS-9137).
Advertisement
Newsfeed
Treatment News
Features
Opinions